Physician profile
Jonathan L Manzer
NPI 1407848971
$7,562.21
in general payments reported to CMS, 2019-2025
46 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,656 · 2020: $418 · 2021: $667 · 2022: $1,388 · 2023: $987 · 2024: $1,040 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,433.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $916.92 | 2019-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Novo Nordisk INC | $748.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $539.02 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.55 | 2019-2025 | Jardiance |
| Pfizer INC. | $350.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $316.83 | 2019-2023 | Segluromet, Belsomra, Steglatro |
| Abbott Laboratories | $278.67 | 2021-2023 | Freestyle Libre |
| Glaxosmithkline, LLC. | $267.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $259.29 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $243.08 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.20 | 2019-2025 | Xifaxan |
| Allergan, INC. | $182.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.69 | 2021-2023 | |
| Dexcom, INC. | $150.15 | 2021-2025 | Dexcom G6 Transmitter |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Manzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.